Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
IMMUNOBIL
Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.
- NCT03704480 ↗
- Active, not recruiting
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Focused
We haven't built an HCP commentary report on IMMUNOBIL (durvalumab plus tremelimumab; durvalumab plus tremelimumab plus paclitaxel in advanced biliary tract carcinoma after platinum-based chemotherapy failure) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IMMUNOBIL so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Advanced Biliary Tract Carcinoma
- Interventions
- Durvalumab; Tremelimumab
- Arms
- Amended ARM A · Experimental
- Enrollment
- 106 (estimated)
- Primary outcomes
- Overall Survival (OS) in amended Arm A
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group with AstraZeneca
- Start
- Nov 9, 2018
- Primary completion
- Jul 28, 2022
- Results posted
- No
- Registry record
- NCT03704480 · updated Jul 23, 2025
Publications
linked from the registry- Boileve A, Hilmi M, Gougis P, Cohen R, Rousseau B, Blanc JF, Ben Abdelghani M, Castanie H, Dahan L, Tougeron D, Metges JP, Tournigand C, Garcia-Larnicol ML, Vernerey D, Turpin A, Neuzillet C. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. Eur J Cancer. 2021 Jan;143:55-63. doi: 10.1016/j.ejca.2020.10.027. Epub 2020 Dec 3. PubMed 33279854